FLEMINGTON, N.J.--(BUSINESS WIRE)--Novadel Pharma, Inc. (the “Company”) (OTCBB: NVDL) announces it has entered into an amendment agreement with ProQuest Investments L.P. and its affiliates (collectively, “ProQuest”) to convert the outstanding aggregate principal balance of all convertible notes and all liquidated damages notes, in each case, plus all accrued interest, in an aggregate amount equal to $3,657,000 to 23,237,083 shares of the Company’s common stock as of December 31, 2009.
